Home / Market News / $DGX
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

Rothschild & Co Redburn Adjusts Price Target on Quest Diagnostics to $279 From $251

Oct 27, 2026, 11:34 AM UTC · Primary ticker $DGX

Rothschild & Co Redburn has increased its price target for Quest Diagnostics from $251 to $279. This indicates a more optimistic outlook from the firm regarding the company's future performance, which could lead to positive investor sentiment.

Rothschild & Co Redburn has raised its price target for Quest Diagnostics (DGX) from $251 to $279. This adjustment signals a more favorable view from the analyst firm on the company's valuation and future prospects. For traders, this could generate short-term positive momentum as investors react to the upgraded outlook, potentially driving the stock price higher. The long-term implications depend on whether the underlying fundamentals of Quest Diagnostics align with this increased valuation. A key opportunity for traders is to capitalize on any immediate upward movement, while the risk lies in the possibility that the market has already priced in such analyst upgrades or that other factors could overshadow this positive news.

$DGX positive Price target increase
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.